Loading data for KROS — first visit, this takes a few seconds.

알림

Keros Therapeutics Inc. (KROS)

NasdaqGM: KROS · 실시간 가격 · USD

11.03

+0.08 (0.73%)

종가 기준: Aug 21, 2026, 8:00 PM

11.03

+0.00%

애프터마켓: 4:10 PM

주가와 핵심 숫자, 최신 뉴스를 한 곳에 모았습니다.

0.73% (1D)

데이터 없음

매수호가	7.33
시가총액	218.69M
매출 (ttm)	15.01M
순이익 (ttm)	-83.16M
	1.01
	-3.25
	n/a
	-1.67
P/B (ttm)	0.83
P/S (ttm)	14.57
실적 발표일	Nov 4, 2026

매도호가	13.08
거래량	153,223
평균 거래량 (20일)	253,519
시가	10.96
전일 종가	10.95
일중 범위	10.80 - 11.09
52주 범위	9.69 - 22.55
애널리스트	n/a
목표주가	n/a
배당	n/a
배당락일	n/a

KROS 소개

Keros Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops and commercializes novel therapeutics to treat patients with disorders linked to dysfunctional signaling of the transforming growth factor-beta family of proteins in the United States. It develops rinvatercept, which acts as a ligand trap and inhibits the biological effects of myostatin and activin A in Phase 1 clinical trials for Duchenne Muscular Dystrophy and Amyotr...

[더 보기]

산업 Biotechnology

섹터 Healthcare

IPO 일자 Apr 8, 2020

직원 수 92

상장 거래소 NasdaqGM

티커 KROS

웹사이트 https://www.kerostx.com

전체 기업 정보

재무 실적

2025년 Keros Therapeutics의 매출은 244.06M로, 전년 3.55M 대비 6,774.96% 증가했습니다. 순이익은 87.01M로, -146.44% 감소했습니다.

재무제표

어닝 서프라이즈

Keros Therapeutics가 Aug 3, 2026에 분기 실적을 발표했습니다:

매출 $0 예상치 하회 $0, 및 -100.00% 전년 대비 감소.
EPS -1.45 예상치 하회 -0.21, 및 -90.79% 전년 대비 감소.

다음 실적 발표

Keros Therapeutics Inc.의 실적 발표 예정일은 Nov 4, 2026, 정규장 중입니다.
애널리스트 예상 매출은 ... 업그레이드

뉴스

1주 전 · Insider Monkey

Can Keros Therapeutics (KROS)’s $20M Takeda Pharmaceutical Company Limited (TAK) Milestone Unlock a Billion-Dollar Opportunity?

On July 30, Keros Therapeutics, Inc. (NASDAQ:KROS) triggered a $20 million development milestone payment from its global partner Takeda Pharmaceutical Company Limited (NYSE:TAK). The payout followed t...

2주 전 · Zacks

KROS Q2 Earnings Miss as Revenues Fall to Zero, Pipeline in Focus

Keros posts a wider Q2 loss as revenues fall to zero, while cash runway into H1 2028 and rinvatercept pipeline milestones keep attention on future growth.

3주 전 · Zacks

Incyte (INCY) Q2 Earnings and Revenues Top Estimates

Incyte (INCY) delivered earnings and revenue surprises of +54.50% and +14.71%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?

1개월 전 · Zacks

Nurix Therapeutics (NRIX) Soars 16.4%: Is Further Upside Left in the Stock?

Nurix Therapeutics (NRIX) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions could translate into further price inc...

3개월 전 · Zacks

KROS Turns to Next Wave of TGF-Beta Muscle Therapies

Keros is shifting toward rinvatercept-led neuromuscular development, with phase II plans, early human signals and cash runway shaping the KROS story.

2 페이지 중 1

Keros Therapeutics Inc. (KROS)